Our present work demonstrated the feasibility of a sensitivity-enhanced tracer in FP assays for APC–Asef inhibitor screening and validated the effective inhibitor MAIT-516 as a potential candidate in future drug development for CRC therapy. This evidence concerns the gene APC and colorectal carcinoma.